# A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

> **NCT04787887** · PHASE1 · COMPLETED · sponsor: **ISU Abxis Co., Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Abcertin
- **DRUG:** EU-sourced Cerezyme

## Key facts

- **NCT ID:** NCT04787887
- **Lead sponsor:** ISU Abxis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-29
- **Primary completion:** 2020-09-27
- **Final completion:** 2020-10-26
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787887, "A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04787887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*